Drug Trial Radar · NCT07836660
A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
198
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Nov 1, 2027
Study completion Oct 31, 2028
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IBI355 in participants with moderate-to-severe Sj?gren's disease (SjD).
Conditions
- Sjögren's Disease
Interventions
Part A - Placebo for IBI355Drug
Matching placebo of IBI355, IV ,corresponding dose regimen according to study design
Part B -TelitaciceptDrug
Telitacicept 160 mg SC QW × 24 doses (Weeks 0-24).
PartB -Placebo for TelitaciceptDrug
Matching placebo of Talitacicept ,SC QW × 24 doses.
Part A - IBI355Drug
IBI355,IV,corresponding dose regimen according to study design
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24Time frame: Baseline and Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.